Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: analysis of the placebo arm of the SPCG-6 study

With up to 15.6 years follow-up after inclusion in the SPCG-6 study, we found no association between PSA kinetics and prostate cancer mortality in patients with localised prostate cancer and PSA at consent ≤10 ng/mL managed observationally. Our findings indicate that the usefulness of PSA kinetics as a surrogate for tumour aggressiveness depends on baseline PSA level.

from Cancer via ola Kala on Inoreader http://ift.tt/1mcKUXc
via IFTTT